Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)

Yoshino, Gen; Kazumi, Tsutomu; Iwai, Masahide; Matsushita, Masayuki; Matsuba, Kohji; Uenoyama, Rinzo; Iwatani, Ippei; Baba, Shigeaki

doi:10.1016/0021-9150(89)90208-6

Cited by 42 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lovastatin , simvastatin ) and pravastatin (Yoshino et al 1989) have been shown to have beneficial effects on plasma lipid and lipoprotein levels in patients with diabetes mellitus, without any adverse effects on blood glucose level, haemoglobin Ale, or insulin action. Although the combination ofHMG-CoA reductase inhibitors and fibric acid derivatives significantly lowers VLDL and LDL, it is associated with an increased risk of myopathy and rhabdomyolysis (Pierce et al 1990).…”

Section: Pharmacological Therapy Of Dyslipidaemiamentioning

confidence: 99%

Treatment of Non-Insulin-Dependent Diabetes Mellitus and its Complications

Ilarde¹,

Tuck

1994

Drugs & Aging

View full text Add to dashboard Cite

Non-insulin-dependent diabetes mellitus (NIDDM) is a major health problem which occurs predominantly in the older population; 16.8% of persons over age 65 years have NIDDM. The total health costs of NIDDM are in excess of $US20 billion annually. The primary objective in the treatment of NIDDM is to achieve normoglycaemia, without aggravating coexisting abnormalities. Common abnormalities include obesity, hypertension, retinopathy, nephropathy and neuropathies. Diet, and consequent bodyweight reduction, is the cornerstone of therapy for NIDDM. Total calorie intake should be limited, while the percentage of calories from carbohydrates should be increased and that from fats and cholesterol should be decreased. Exercise may also help to reduce bodyweight. Sulphonylurea drugs stimulate insulin secretion from beta-cells, and may be a useful adjunct to nonpharmacological therapy. Failure to respond to sulphonylurea drugs may be primary (25 to 30% of initially treated patients) or secondary (5 to 10% per year). It is not clear which is the most effective pharmacological intervention in such cases. Options include switching to or combining therapy with insulin, a biguanide, or other insulin-sparing antihyperglycaemic agents, e.g. alpha-glucosidase inhibitors, thiazolidinediones, chloroquine or hydroxychloroquine, or fibric acid derivatives such as clofibrate. Other experimental agents include the fatty acid oxidation inhibitors and dichloroacetate. Specific agents, such as antihypertensives, lipid lowering agents and sorbitol inhibitors, may be needed to prevent the complications arising from the spectrum of clinical and metabolic abnormalities which arise from insulin resistance.

show abstract

Section: Pharmacological Therapy Of Dyslipidaemiamentioning

confidence: 99%

Treatment of Non-Insulin-Dependent Diabetes Mellitus and its Complications

Ilarde¹,

Tuck

1994

Drugs & Aging

View full text Add to dashboard Cite

show abstract

“…Lovastatin (Garg & Grundy 1988), simvastatin (Lintott et al 1992) and pravastatin (Yoshino et al 1989) have all shown beneficial effects on plasma lipid and lipoprotein levels in patients with diabetes mellitus, without any adverse effect on blood glucose level, haemoglobin Ale, or insulin action.…”

Section: 26 Use In Patients With Diabetes Mellitusmentioning

confidence: 97%

HMG-CoA Reductase Inhibitor Use in the Aged

Lintott

Scott

1992

Drugs & Aging

View full text Add to dashboard Cite

While the benefit of cholesterol-lowering in the elderly has yet to be proven in clinical trials, individuals at high risk of coronary events who otherwise enjoy a good quality of life, should not be denied cholesterol-lowering therapy on the basis of age alone. Moreover, hypolipidaemic drugs are already extensively used in the aged. The HMG-CoA reductase inhibitors lovastatin, simvastatin and pravastatin are potent well tolerated hypolipidaemic therapies in young subjects. Although there have been few studies on their use in elderly subjects, the available data suggest the efficacy and safety of HMG-CoA reductase inhibitors in similar to that established for younger age groups.

show abstract

“…Treatment with statins also reduces apolipoprotein B levels, and at typical doses, increases apolipoprotein A-1. Long-term therapy (6-12 months) with statins is well tolerated by diabetic patients [40][41][42][43][44]. Statin therapy is not associated with alterations in glucose control as measured by fasting glucose and glycated hemoglobin A 1c (HbA 1c ) levels.…”

Section: Statin Therapymentioning

confidence: 99%

Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy

Marcus¹

2001

The Endocrinologist

View full text Add to dashboard Cite

Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)

Cited by 42 publications

References 27 publications

Treatment of Non-Insulin-Dependent Diabetes Mellitus and its Complications

Treatment of Non-Insulin-Dependent Diabetes Mellitus and its Complications

HMG-CoA Reductase Inhibitor Use in the Aged

Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy

Contact Info

Product

Resources

About